Diana Torres
Acute Care · Rogers, ARNPI 1861077802
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.
Across 159 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$440
- AstraZeneca$404
- GSK$385
- Grifols USA, LLC$326
- Boehringer Ingelheim$325
- Mallinckrodt Hospital Products Inc.$224
- plus $2K from 21 others
What the payments were for
- Food & beverage$3,62198%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 12 | $440 |
| AstraZeneca(2 entities) | 18 | $404 |
| GSK | 18 | $385 |
| Grifols USA, LLC | 12 | $326 |
| Boehringer Ingelheim | 18 | $325 |
| Mallinckrodt Hospital Products Inc. | 9 | $224 |
| Sanofi | 8 | $206 |
| Merck | 8 | $182 |
| United Therapeutics Corporation | 6 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $125 |
| Mylan Specialty L.p. | 7 | $122 |
| Baxter Healthcare | 5 | $118 |
| AbbVie | 4 | $86 |
| Gilead | 4 | $71 |
| Pfizer | 4 | $66 |
| Insmed, Inc. | 3 | $59 |
| Philips North America LLC | 3 | $57 |
| Inari Medical, Inc. | 2 | $50 |
| Electromed, Inc. | 3 | $50 |
| Aimmune Therapeutics, Inc. | 1 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Advanced Respiratory, Inc | 2 | $31 |
| Chiesi USA, Inc. | 1 | $29 |
| Harmony Biosciences LLC | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$124
- DUPIXENT$123
How this compares
$3,696 in reported general payments places this provider in the 85th percentile of 321 acute care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $88,386 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $24,203 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $10,459 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 70 | $5,823 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,873 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $3,953 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $2,172 |
| Roflumilast | 40 | $2,136 |
| Arnuity ElliptaFluticasone Furoate | 11 | $1,761 |
| Ventolin HfaAlbuterol Sulfate | 29 | $1,585 |
| Montelukast Sodium | 47 | $380 |
| Fluticasone Propionate | 29 | $366 |
| Pantoprazole Sodium | 26 | $364 |
| Prednisone | 28 | $113 |
| Azithromycin | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $385 | $114,349178 claims |
| AstraZenecaSymbicort, Bevespi Aerosphere | $404 | $14,41252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 321 acute care providers in Arkansas.
Other acute care in Rogers
- Jill AveryLittle Rock$117K
- Lynn FrazierLittle Rock$106K
- Cheryl WalshSpringdale$101K
- Beverly BaxterLittle Rock$95K
- Diane GlendinningLittle Rock$26K
- Beth CrowderLittle Rock$25K
- Carmen Paniagua TorresLittle Rock$21K
- Jennifer HocuttHot Springs$15K
- Shana KloskeLittle Rock$14K
- Teri SmithHot Springs National Park$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.